新型微创治疗在良性前列腺增生相关下尿路症状中的作用
本文为非系统性综述,更新了Aquablation、水蒸气热疗、前列腺动脉栓塞、前列腺尿道提升术和临时可植入镍钛装置等新型微创治疗LUTS/BPH的文献、荟萃分析及指南推荐。结论指出门诊可完成的操作并非标准BPH手术的替代,对尿流、残余尿或膀胱出口梗阻的改善弱于TURP,但适合手术 unfit、不愿药物治疗或想避免性副作用者;Aquablation尤其适用于前列腺>50g患者,所有新疗法均需长期数据。
要点
- 门诊微创治疗改善尿流、残余尿和梗阻弱于TURP,非标准手术替代。
- 适合手术 unfit、不愿药物或想避免性副作用(含TURP相关)的患者。
- Aquablation是首个成功运行的机器人切除系统,尤其适用于前列腺>50g。
核心结论
- 新型微创治疗对尿流、残余尿或膀胱出口梗阻的改善不如TURP,但可用于特定人群。
- Aquablation尤其适用于前列腺>50g患者,但所有新疗法均需长期数据。
- 需要更好的临床试验设计、明确目标人群和更现实的营销来刻画这些疗法。
研究设计与样本
- 非系统性综述,回顾Aquablation、Rezūm、PAE、UroLift和i-TIND的最新文献、荟萃分析与指南推荐。
主要发现
- Rezūm、PAE、UroLift和i-TIND可在门诊完成,对尿流、残余尿或梗阻的改善弱于TURP。
- 这些门诊操作对手术 unfit、不愿药物治疗或想避免性副作用者是 valuable 选项。
- Aquablation是首个成功运行的机器人切除系统,尤其适用于前列腺>50g患者。
临床怎么用
- 门诊微创治疗不替代标准BPH手术,应选择手术 unfit、不愿药物或想避免性副作用者。
- Aquablation可考虑用于前列腺>50g患者,但需告知长期数据有限。
局限性
- 非系统性综述,未提供系统检索策略。
- 所有新型微创治疗均缺乏长期数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To provide an update on novel minimally invasive lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) treatments in a non-systematic review. To define potential target populations for the various new minimally invasive treatments. METHODS: Recent literature, meta-analyses and guideline recommendations for aquablation (AquaBeam® ; PROCEPT BioRobotics, Redwood City, CA, USA), water vapour thermal therapy (Rezūm® ; Boston Scientific, Natick, MA, USA), prostate artery embolisation (PAE), prostatic urethral lift (UroLift® ; NeoTract-Teleflex, Pleasanton, CA, USA) and the temporary implantable nitinol device [i-TIND® (nitinol butterfly-like stent ); Medi-Tate Ltd., Or-Akiva, Israel] were reviewed. RESULTS: Procedures that can be performed on an outpatient basis (Rezūm, PAE, UroLift and i-TIND) are not an alternative for the standard patient requiring BPH surgery. Their effect on urinary flow, post-void residual urine volume or bladder outlet obstruction is less pronounced than that of transurethral resection of the prostate (TURP). Yet, these options appear to be valuable for those patients unfit for surgery, men who want to avoid medical therapy in general, or those who want to avoid sexual side-effects associated with medical therapy or standard BPH surgery (e.g. TURP). Aquablation is the first successfully operationalised robotic resection system, especially for patients with prostates >50 g. Nevertheless, long-term data are necessary for all novel, minimally invasive treatments. CONCLUSIONS: Better designed clinical trials, a clearer definition of target populations and a more realistic marketing allow a better characterisation of novel minimally invasive therapies for LUTS/BPH. It is hoped that some of these novel devices will stand the test of time, in contrast to the vast majority of their predecessors.
引用
- Madersbacher S, Roehrborn CG, Oelke M, et al. The role of novel minimally invasive treatments for lower urinary tract symptoms associated with benign prostatic hyperplasia. BJU Int. 2020. PMID: 32599656. doi:10.1111/bju.15154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。